Research programme: abuse-resistant opioid analgesics - DURECT Corporation

Drug Profile

Research programme: abuse-resistant opioid analgesics - DURECT Corporation

Alternative Names: Abuse-resistant oxymorphone; ORADUR-Oxymorphone

Latest Information Update: 13 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DURECT Corporation
  • Class Morphine derivatives; Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 13 Jul 2017 Preclinical trials in Pain (Abuse-resistant) in USA (PO) (DURECT Corporation pipeline, July 2017)
  • 16 Nov 2013 Suspended - Preclinical for Pain in USA (PO)
  • 31 Oct 2013 Pfizer terminates its licence for the programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top